Abstract 1341P
Background
The aim of PISCES study is to assess the molecular testing, treatment patterns and clinical outcomes among Chinese patients progressed on first-line (1L) EGFR-TKI monotherapy in real-world setting.
Methods
This prospective study enrolled EGFR mutant, locally advanced or metastatic NSCLC patients progressed on 1L EGFR-TKI monotherapy from May 2020 to May 2021 in 16 Chinese hospitals. The treatment patterns and clinical outcomes were recorded.
Results
292 patients received 1L EGFR-TKI monotherapy were enrolled. 93.8% (274/292) of patients received first/second generation (1/2G) EGFR-TKI and 6.2% (18/292) received third generation (3G) EGFR-TKI. 74.8% (205/274) of patients who progressed on 1L 1/2G EGFR-TKI underwent genetic testing, and 47.8% (98/205) of them were T790M positive (T790M+). 91.8% (90/98) of T790M+ patients received 3G EGFR-TKI as 2L therapy. Among the 107 patients with T790M negative (T790M-), 47.8% (51/107) received 3G EGFR-TKI, 25.2% (27/107) received chemotherapy and 8.4% (9/107) received prior 1/2G EGFR-TKI plus local therapy as 2L therapy. Among 18 patients progressed on 1L 3G EGFR-TKI, half (9/18) of them received chemotherapy, 27.8% (5/18) switched to another 3G EGFR-TKI. The overall median PFS (mPFS) of patients who had received 2L treatment was 9.1 months (95%CI, 7.6-11.2). The mPFS of patients receiving 2L 3G EGFR-TKI, prior 1/2G EGFR-TKI plus local therapy, and chemotherapy was 10.5 months (95%CI, 8.7-13.7), 10.2 months (95%CI, 5.3-19.2) and 5.5 months (95%CI, 3.3-8.6), respectively. Among those receiving 2L 3G EGFR-TKI treatment, T790M+ patients achieved significantly longer mPFS compared to T790M- patients (13.7 vs 7.6 months, P=0.012). For patients with T790M-, the mPFS was comparable (7.6 vs 5.5 months, P=0.07) when received 3G EGFR-TKI and chemotherapy as 2L therapy.
Conclusions
Most patients progressed on 1L EGFR-TKI monotherapy underwent genetic testing in Chinese real-world setting. The vast majority of T790M+ patients received 3G EGFR-TKIs treatment. Although almost half of T790M- patients received 3G EGFR-TKI as 2L therapy, these patients achieved suboptimal clinical outcome.
Clinical trial identification
NCT04207775.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1027P - An open-label, multicenter, phase I/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)
Presenter: Byoung Chul Cho
Session: Poster session 19
1028P - Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Presenter: Daphne Day
Session: Poster session 19
1029P - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Presenter: Anthony Olszanski
Session: Poster session 19
1030P - Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1031P - ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1032P - A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Presenter: Zhi Peng
Session: Poster session 19
1033P - First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
Presenter: Aung Naing
Session: Poster session 19
1034P - Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Presenter: Alexander Starodub
Session: Poster session 19
1035P - Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
Presenter: Ho Yeong Lim
Session: Poster session 19
1036P - A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Presenter: Junli Xue
Session: Poster session 19